Thin
1 / 2
Tirzepatide is specially designed to target two key receptors in the body: glucose-dependent insulin secretagogue polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism of action enables Tirzepatide to simultaneously address multiple aspects of metabolic health, providing a comprehensive solution for people who have difficulty managing their weight.
Tirzepatide is designed to improve glycemic control, reduce body weight, and support overall metabolic health.
It targets two key receptors simultaneously: glucose-dependent insulin secretagogue polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.
It is administered as a once-weekly subcutaneous injection.
Available strengths typically include 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per dose, which are adjusted based on clinical response and tolerability.
Yes, its comprehensive mechanism addresses multiple aspects of metabolic health, making it an effective solution for people who have difficulty managing their weight, and it has been extensively studied in clinical trials for obesity management.
